In the melanoma cohort, ten patients with anti-PD-1-resistant advanced melanoma enrolled at four centers in the US and Canada between February 2019 and May 2020 received combination treatment with ziv-aflibercept and pembrolizumab. The gene discussed is PDCD1; the disease is melanoma.